000963 华东医药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入33,019,1061.09%43,612,01041,905,70740,623,78337,714,587
减:营业总成本29,684,2201.35%39,388,88137,493,02037,081,91534,568,570
    其中:营业成本22,226,1362.35%29,499,47927,988,54727,461,73225,682,497
               财务费用28,367150.42%18,77322,26551,19078,257
               资产减值损失(7,889)--(87,896)(41,006)(6,520)(3,822)
公允价值变动收益--------(13,756)28,469
投资收益(28,772)-75.90%(137,843)(129,191)(219,713)(141,560)
    其中:对联营企业和合营企业的投资收益6,225-108.27%(75,923)(68,453)(188,391)(115,619)
营业利润3,342,798-0.23%4,107,8934,324,7373,452,9273,061,454
利润总额3,261,415-0.04%4,016,4624,301,5143,465,9863,031,124
减:所得税费用512,931-1.50%605,616807,328619,589498,499
净利润2,748,4840.24%3,410,8473,494,1862,846,3972,532,626
减:非控股权益(23,393)286.16%(3,489)(17,919)7,53633,411
股东净利润2,771,8770.87%3,414,3353,512,1052,838,8612,499,214

市场价值指针
每股收益 (元) *1.5810.79%1.9482.0051.6221.428
每股派息 (元) *0.3500.00%0.9300.9300.5800.290
每股净资产 (元) *14.6836.72%14.14513.14511.99710.592
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容